Case Study

Oncology Breakthrough with Direct-to-Patient Supply

Challenge

The oncology research group faced significant challenges in ensuring patient retention and site satisfaction due to the complexity of medication logistics. Patients, especially those in rural and underserved areas, struggled with regular site visits to collect their medications. Additionally, the costs associated with standard-of-care medications posed a financial burden, leading to high dropout rates and delays in trial timelines.

The Myonex Solution

To solve these issues, Myonex introduced the Direct-to-Patient (DTP) supply model within it’s CTRx solution suite. By delivering trial medications directly to patients’ homes, regardless of location, Myonex removed the logistical challenges associated with frequent site visits. Through CTRx’s prescription card, participants received access to their standard-of-care medications at no cost by directly reimbursing pharmacies paid for by the Sponsor, eliminating the financial barriers contributing to patient dropout.

Results

Increased patient retention: The DTP model ensured that patients could stay in the trial without the burden of traveling to sites for medication. Retention rates improved significantly as patients had consistent and convenient access to their treatments.
Higher patient and site satisfaction: Patients appreciated the convenience of home delivery, while trial sites experienced a reduced administrative burden. Both patients and site staff reported increased satisfaction with the streamlined process.
Improved diversity in enrollment: The trial’s DTP supply method allowed medication to reach patients in remote and underserved areas, increasing the diversity of the participant pool.
Compliance: Myonex supported all Sponsor and regulatory requirements related to direct to patient services.

Conclusion

Myonex’s DTP supply model and CTRx solution allowed this oncology trial to overcome critical logistical and financial barriers. The result was higher retention rates, improved site efficiency, and a more diverse trial population, ensuring the study met its recruitment and data collection goals.